{"id":65992,"date":"2026-05-22T21:21:04","date_gmt":"2026-05-22T13:21:04","guid":{"rendered":"https:\/\/flcube.com\/?p=65992"},"modified":"2026-05-22T21:21:05","modified_gmt":"2026-05-22T13:21:05","slug":"gilead-sciences-launches-five-year-who-partnership-to-accelerate-elimination-of-visceral-leishmaniasis-in-high-burden-regions","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=65992","title":{"rendered":"Gilead Sciences Launches Five-Year WHO Partnership to Accelerate Elimination of Visceral Leishmaniasis in High-Burden Regions"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Gilead Sciences, Inc. (<a href=\"https:\/\/www.google.com\/finance\/quote\/GILD:NASDAQ\">NASDAQ: GILD<\/a>)<\/strong> announced a <strong>five-year strategic collaboration<\/strong> with the <strong>World Health Organization (WHO)<\/strong> to accelerate progress toward the <strong>elimination of visceral leishmaniasis (VL)<\/strong>, also known as kala-azar. The partnership includes commitments for <strong>funding, strategic support, and drug donations<\/strong> aimed at improving access to life-saving diagnostic services and treatments for vulnerable populations in high-burden countries, with a renewed focus on <strong>East Africa<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-partnership-structure\" class=\"wp-block-heading\">Partnership Structure<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Partners<\/strong><\/td><td>Gilead Sciences, Inc. (NASDAQ: GILD) and World Health Organization (WHO)<\/td><\/tr><tr><td><strong>Duration<\/strong><\/td><td>Five years (2026\u20132031)<\/td><\/tr><tr><td><strong>Geographic Focus<\/strong><\/td><td>High-burden countries in East Africa<\/td><\/tr><tr><td><strong>Commitment Components<\/strong><\/td><td>Funding, strategic support, and drug donations<\/td><\/tr><tr><td><strong>Target Disease<\/strong><\/td><td>Visceral leishmaniasis (kala-azar)<\/td><\/tr><tr><td><strong>Primary Objective<\/strong><\/td><td>Accelerate elimination of VL through improved diagnostic and treatment access<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-disease-profile-amp-global-burden\" class=\"wp-block-heading\">Disease Profile &amp; Global Burden<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Disease Classification:<\/strong> Visceral leishmaniasis (VL), also known as kala-azar<\/li>\n\n\n\n<li><strong>Mortality Ranking:<\/strong> Second deadliest parasitic disease globally after malaria<\/li>\n\n\n\n<li><strong>Transmission Vector:<\/strong> Sandfly bites<\/li>\n\n\n\n<li><strong>Pathophysiology:<\/strong> Attacks internal organs; fatal if untreated<\/li>\n\n\n\n<li><strong>At-Risk Population:<\/strong> Primarily affects the world&#8217;s most vulnerable populations in resource-limited settings<\/li>\n\n\n\n<li><strong>Current Treatment Landscape:<\/strong> Limited access to diagnostics and effective therapies in endemic regions<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-implementation-framework\" class=\"wp-block-heading\">Strategic Implementation Framework<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Initiative Component<\/th><th>Expected Impact<\/th><\/tr><\/thead><tbody><tr><td><strong>Diagnostic Access Expansion<\/strong><\/td><td>Increased early detection and timely intervention in high-burden communities<\/td><\/tr><tr><td><strong>Treatment Availability<\/strong><\/td><td>Enhanced supply chain for life-saving medications through Gilead drug donations<\/td><\/tr><tr><td><strong>Healthcare System Strengthening<\/strong><\/td><td>Capacity building for local healthcare providers in VL-endemic regions<\/td><\/tr><tr><td><strong>Surveillance Enhancement<\/strong><\/td><td>Improved disease monitoring and outbreak response capabilities<\/td><\/tr><tr><td><strong>Research &amp; Development Support<\/strong><\/td><td>Acceleration of innovative therapeutic approaches for VL elimination<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The collaboration leverages Gilead&#8217;s expertise in antiparasitic drug development and global health partnerships, combined with WHO&#8217;s extensive field presence and public health coordination capabilities in endemic regions.<\/p>\n\n\n\n<h2 id=\"h-global-health-impact-amp-market-context\" class=\"wp-block-heading\">Global Health Impact &amp; Market Context<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Disease Elimination Timeline:<\/strong> Supports WHO&#8217;s 2030 roadmap for neglected tropical disease elimination<\/li>\n\n\n\n<li><strong>Gilead&#8217;s Global Health Portfolio:<\/strong> Expands beyond HIV, hepatitis, and COVID-19 to include neglected tropical diseases<\/li>\n\n\n\n<li><strong>East Africa Focus:<\/strong> Addresses critical gaps in VL care delivery across Sudan, Ethiopia, Kenya, and other high-burden countries<\/li>\n\n\n\n<li><strong>Sustainable Development Alignment:<\/strong> Contributes to UN Sustainable Development Goal 3 (Good Health and Well-being)<\/li>\n\n\n\n<li><strong>Industry Leadership:<\/strong> Demonstrates pharmaceutical industry commitment to addressing diseases affecting underserved populations<\/li>\n\n\n\n<li><strong>Financial Commitment:<\/strong> Multi-million dollar investment over five years, though specific figures were not disclosed<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding the partnership&#8217;s objectives and expected outcomes. Actual results may differ due to risks including implementation challenges in resource-limited settings, regulatory requirements, political instability in target regions, and competing public health priorities.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Gilead Sciences, Inc. (NASDAQ: GILD) announced a five-year strategic collaboration with the World Health Organization&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[226,1025],"class_list":["post-65992","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-gilead-sciences","tag-nasdaq-gild"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Gilead Sciences Launches Five-Year WHO Partnership to Accelerate Elimination of Visceral Leishmaniasis in High-Burden Regions - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Gilead Sciences, Inc. (NASDAQ: GILD) announced a five-year strategic collaboration with the World Health Organization (WHO) to accelerate progress toward the elimination of visceral leishmaniasis (VL), also known as kala-azar. The partnership includes commitments for funding, strategic support, and drug donations aimed at improving access to life-saving diagnostic services and treatments for vulnerable populations in high-burden countries, with a renewed focus on East Africa.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=65992\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Gilead Sciences Launches Five-Year WHO Partnership to Accelerate Elimination of Visceral Leishmaniasis in High-Burden Regions\" \/>\n<meta property=\"og:description\" content=\"Gilead Sciences, Inc. (NASDAQ: GILD) announced a five-year strategic collaboration with the World Health Organization (WHO) to accelerate progress toward the elimination of visceral leishmaniasis (VL), also known as kala-azar. The partnership includes commitments for funding, strategic support, and drug donations aimed at improving access to life-saving diagnostic services and treatments for vulnerable populations in high-burden countries, with a renewed focus on East Africa.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=65992\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-22T13:21:04+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-22T13:21:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65992#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65992\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Gilead Sciences Launches Five-Year WHO Partnership to Accelerate Elimination of Visceral Leishmaniasis in High-Burden Regions\",\"datePublished\":\"2026-05-22T13:21:04+00:00\",\"dateModified\":\"2026-05-22T13:21:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65992\"},\"wordCount\":418,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Gilead Sciences\",\"NASDAQ: GILD\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65992#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65992\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=65992\",\"name\":\"Gilead Sciences Launches Five-Year WHO Partnership to Accelerate Elimination of Visceral Leishmaniasis in High-Burden Regions - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-05-22T13:21:04+00:00\",\"dateModified\":\"2026-05-22T13:21:05+00:00\",\"description\":\"Gilead Sciences, Inc. (NASDAQ: GILD) announced a five-year strategic collaboration with the World Health Organization (WHO) to accelerate progress toward the elimination of visceral leishmaniasis (VL), also known as kala-azar. The partnership includes commitments for funding, strategic support, and drug donations aimed at improving access to life-saving diagnostic services and treatments for vulnerable populations in high-burden countries, with a renewed focus on East Africa.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65992#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65992\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65992#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Gilead Sciences Launches Five-Year WHO Partnership to Accelerate Elimination of Visceral Leishmaniasis in High-Burden Regions\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Gilead Sciences Launches Five-Year WHO Partnership to Accelerate Elimination of Visceral Leishmaniasis in High-Burden Regions - Insight, China&#039;s Pharmaceutical Industry","description":"Gilead Sciences, Inc. (NASDAQ: GILD) announced a five-year strategic collaboration with the World Health Organization (WHO) to accelerate progress toward the elimination of visceral leishmaniasis (VL), also known as kala-azar. The partnership includes commitments for funding, strategic support, and drug donations aimed at improving access to life-saving diagnostic services and treatments for vulnerable populations in high-burden countries, with a renewed focus on East Africa.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=65992","og_locale":"en_US","og_type":"article","og_title":"Gilead Sciences Launches Five-Year WHO Partnership to Accelerate Elimination of Visceral Leishmaniasis in High-Burden Regions","og_description":"Gilead Sciences, Inc. (NASDAQ: GILD) announced a five-year strategic collaboration with the World Health Organization (WHO) to accelerate progress toward the elimination of visceral leishmaniasis (VL), also known as kala-azar. The partnership includes commitments for funding, strategic support, and drug donations aimed at improving access to life-saving diagnostic services and treatments for vulnerable populations in high-burden countries, with a renewed focus on East Africa.","og_url":"https:\/\/flcube.com\/?p=65992","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-22T13:21:04+00:00","article_modified_time":"2026-05-22T13:21:05+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=65992#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=65992"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Gilead Sciences Launches Five-Year WHO Partnership to Accelerate Elimination of Visceral Leishmaniasis in High-Burden Regions","datePublished":"2026-05-22T13:21:04+00:00","dateModified":"2026-05-22T13:21:05+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=65992"},"wordCount":418,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Gilead Sciences","NASDAQ: GILD"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=65992#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=65992","url":"https:\/\/flcube.com\/?p=65992","name":"Gilead Sciences Launches Five-Year WHO Partnership to Accelerate Elimination of Visceral Leishmaniasis in High-Burden Regions - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-05-22T13:21:04+00:00","dateModified":"2026-05-22T13:21:05+00:00","description":"Gilead Sciences, Inc. (NASDAQ: GILD) announced a five-year strategic collaboration with the World Health Organization (WHO) to accelerate progress toward the elimination of visceral leishmaniasis (VL), also known as kala-azar. The partnership includes commitments for funding, strategic support, and drug donations aimed at improving access to life-saving diagnostic services and treatments for vulnerable populations in high-burden countries, with a renewed focus on East Africa.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=65992#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=65992"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=65992#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Gilead Sciences Launches Five-Year WHO Partnership to Accelerate Elimination of Visceral Leishmaniasis in High-Burden Regions"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65992","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=65992"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65992\/revisions"}],"predecessor-version":[{"id":65993,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65992\/revisions\/65993"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=65992"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=65992"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=65992"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}